Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia
American Journal of Hematology · 2026-12 · 101 (12) · 2957-2960
DOI: 10.1002/ajh.70510 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 28.09.2026. Verfasst von Andrew B Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Classical Hematology, Mass General Brigham Cancer Institute, Boston, Massachusetts, USA. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Classical Hematology, Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- University of Miami Health System, Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
ORCID-Profile: Andrew B Song, Gerald A Soff
Zitieren
APA
Song, A. B., & Soff, G. A. (2026). Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia. American Journal of Hematology, 101(12), 2957-2960. https://doi.org/10.1002/ajh.70510
Vancouver
Song AB, Soff GA. Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia. American Journal of Hematology. 2026;101(12):2957-2960. doi:10.1002/ajh.70510
BibTeX
@article{Song2026,
author = {Song, Andrew B and Soff, Gerald A},
title = {Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {12},
pages = {2957--2960},
doi = {10.1002/ajh.70510}
}
EUVIMED